Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (8253)	12/17/2001 8:13:00 PM
From: David Graham	Respond to of 14101

Hey CG, still here, reading everything. We're still dealing with the chicken and egg problem. The largest funds that have the most $$$$ only buy stocks with big market caps, i.e. the top 100 or so on the TSE. Everything else is too hard to get into or out of. The only two Canadian pharmas commonly owned are Biovail and QLT - this reinforces the preference for significant sales and cash flow. However, QLT did go bananas when the FDA approval came through. Though realistically, the company had had tons/tonnes of press coverage prior to that, much more than DMX has seen. There are only a handful of small cap managers in the country who are likely buyers in the near future, and probably some decent sized investment counsellors (Those with $100 or $200 million in assets). The biggest boys will only dabble at best. To answer your question, yes, they'll generally buy in chunks crossed by some broker. First the broker will accumulate the required # of shares in a bunch of smaller transactions and then the larger cross will signal the sale to the client account. I have to confess that I was sorely tempted to dump this stock when it dipped below $4.00. Obviously, I'm glad that I didn't. Does anybody follow Paladin Labs (PLB)? It seems like an interesting little company.